Journey

Journey

We’ve demonstrated positive momentum since we opened our doors.

See all archived press releases here.

  • 4Q: 2018
    NOVEMBER:
    • Renalytix secures $29.1 million in funding to support the development and commercialization of two product categories for the early detection of kidney disease and accurate management of kidney transplant rejection
  • 1Q: 2019
    MARCH:
    • Renalytix requests parallel CMS reimbursement review of KidneyIntelX with the FDA review
    • Renalytix requests Breakthrough Device Designation of KidneyIntelX from the FDA
  • 2Q: 2019
    APRIL:
    • Renalytix published manuscript outlining positive results that demonstrated the performance characteristics of our machine learning algorithm combining biomarkers and EHR data to predict fast progressing kidney disease


    MAY:
    • FDA grants Breakthrough Device Designation to Renalytix for its KidneyIntelX test, identifying it as a breakthrough technology for which no approved or cleared alternative exists and meeting the criteria of providing a more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease
  • 3Q: 2019
    JULY:
    • Renalytix raises gross proceeds in follow-on financing on the AIM market, $17.3M
    • Renalytix announces positive interim study results conducted with leading academic medical centers in the US


    SEPTEMBER:
    • Renalytix achieves inclusion on the Final 2020 Clinical Laboratory Fee Schedule (“CLFS”) with a set national price of $950 per reportable test for our KidneyIntelX test platform (effective January 2020 through December 2022).
  • 4Q: 2019
    OCTOBER:
    • Renalytix obtains a distinct Common Procedural Terminology (CPT) reimbursement code 0105U, for its KidneyIntelX platform, effective across the U.S.


    DECEMBER:
    • Renalytix opens second CLIA-authorized testing facility, Utah
  • 1Q: 2020
    FEBRUARY:
    • Renalytix receives ISO 13485 certification for its Salt Lake City Laboratory
  • 2Q: 2020
    MAY:
    • Renalytix proposes dual-listing on NASDAQ


    JUNE:
    • Renalytix is granted a Clinical Laboratory Permit for KidneyIntelX from the NYS Department of Health, following an extensive review by a panel of Department of Health scientists and external reviewers of the analytical and clinical validation results
    • Renalytix announces partnership with University of Michigan to extend its KidneyIntelX platform to an expanded population of CKD patients or patients at risk for developing CKD
  • 3Q: 2020
    JULY:
    • Renalytix raises $85.1M on the NASDAQ Global Market in the U.S.
    • Renalytix signs agreement to become a provider in the America’s Choice Provider Network, one of the largest, preferred networks in the US with members and providers in all 50 states and agreement with 1700+ payers


    AUGUST:
    • Renalytix announces partnership with Astra-Zeneca, teaming up to improve CKD treatments and outcomes
    • Renalytix files submission with FDA, seeking clearance of its KidneyIntelX test platform
    • Renalytix commences with a KidneyIntelX Multi-Center Study to monitor & predict kidney risk in COVID-19 patients


    SEPTEMBER:
    • Renalytix initiates KidneyIntelX Testing at Mount Sinai, with its first live EHR Integration
  • 1Q: 2021
    JANUARY:
    • Renalytix signs multi-geography, U.S. partnership with DaVita, an end-to-end kidney solution


    FEBRUARY:
    • The University of Utah and Renalytix form partnership to enable health system-wide approach to help delay or prevent kidney disease progression in the earliest stages
  • 2Q: 2021
    APRIL:
    • Multi-Center Study finds KidneyIntelX 72% more effective than the current standard of care in identifying early-stage patients at higher risk for disease progression and failure
    • Clinical Utility Study demonstrates that primary care physicians highly likely to order KidneyIntelX to inform care decisions
    • Renalytix and Joslin Diabetes Center enter exclusive option agreement for patent filings on select additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX platform
    • KidneyIntelX demonstrates performance and informs treatment decisions in multinational CANagliflozin CardioVAScular Assessment Study (CANVAS)
    • U.S. General Services Administration grants 10-year governmentwide contract for KidneyIntelX testing


    MAY:
    • Renalytix partners with Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine to reduce impact of kidney disease in large populations


    JUNE:
    • Utility Study indicates KidneyIntelX risk assessment can address treatment ambiguity in primary care
    • Renalytix announces new data demonstrating that KidneyIntelX can be effective at monitoring SGLT2 therapeutic response and improvements in kidney health over time in adults with Type 2 diabetes